SLC5A2 and type 2 diabetes mellitus: While SGLT2 inhibitors offer significant benefits and show great promise in their multifaceted approach to the management of T2DM and heart failure by virtue of their cardiovascular benefits, they have the potential to cause rare adverse effects, most notably, in some cases, pancreatitis.